An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells

Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques

(2019) Huihui Chong et al.   PLoS Pathogens

IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies

(2019) Wenwen Bi et al.   PLoS Pathogens

A Novel gp41-Binding Adnectin with Potent Anti-HIV Activity Is Highly Synergistic when Linked to a CD4-Binding Adnectin

(2018) David Wensel et al.   JOURNAL OF VIROLOGY

Antiretroviral implants for treatment and prevention of HIV infection

(2018) Charles Flexner   Current Opinion in HIV and AIDS

Barriers and strategies to achieve a cure for HIV

(2018) Matthew C Pitman et al.   Lancet HIV

HIV

(2018) Jade Ghosn et al.   LANCET

Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency

(2018) Sushama Telwatte et al.   PLoS Pathogens

An Amphibian Host Defense Peptide Is Virucidal for Human H1 Hemagglutinin-Bearing Influenza Viruses

(2017) David J. Holthausen et al.   IMMUNITY

A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro , Ex Vivo , and In Vivo Antiviral Activity

(2017) Huihui Chong et al.   JOURNAL OF VIROLOGY

Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus

(2017) Wenqian Yang et al.   MICROBES AND INFECTION

Defining total-body AIDS-virus burden with implications for curative strategies

(2017) Jacob D Estes et al.   NATURE MEDICINE

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

(2017) Marina Caskey et al.   NATURE MEDICINE

Solution Structure and Membrane Interaction of the Cytoplasmic Tail of HIV-1 gp41 Protein

(2017) R. Elliot Murphy et al.   STRUCTURE

A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses

(2017) Yufeng Yu et al.   Nature Communications

Advancements in Developing Strategies for Sterilizing and Functional HIV Cures

(2017) Wei Xu et al.   Biomed Research International

HIV-1 Env DNA prime plus gp120 and gp70-V1V2 boosts induce high level of V1V2-specific IgG and ADCC responses and low level of Env-specific IgA response: implication for improving RV144 vaccine regimen

(2017) Qian Wang et al.   Emerging Microbes & Infections

HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions

(2017) Qianqian Qi et al.   Emerging Microbes & Infections

TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells

(2016) Rujuta A. Bam et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

HIV Reservoir: Finding the Right Needles in a Needlestack

(2016) Alexander O. Pasternak et al.   Cell Host & Microbe

Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth

(2016) Jinghe Huang et al.   IMMUNITY

Loss of cerebellar neurons in the progression of lentiviral disease: effects of CNS-permeant antiretroviral therapy

(2016) Christian Wächter et al.   Journal of Neuroinflammation

Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors

(2016) Shan Su et al.   JOURNAL OF VIROLOGY

Elimination of HIV-1-infected cells by broadly neutralizing antibodies

(2016) Timothée Bruel et al.   Nature Communications

An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene

(2016) Zhiwu Sun et al.   Emerging Microbes & Infections

Rational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations

(2016) Yun Zhu et al.   Scientific Reports

Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy

(2015) Qian Wang et al.   JOURNAL OF VIROLOGY

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

(2015) Marina Caskey et al.   NATURE

Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations

(2015) Kai Deng et al.   NATURE

The I-TASSER Suite: protein structure and function prediction

(2015) Jianyi Yang et al.   NATURE METHODS

Cell-Penetrating Peptides Selectively Cross the Blood-Brain Barrier In Vivo

(2015) Sofie Stalmans et al.   PLoS One

Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat–C-terminal heptad repeat interactions and C-peptides’ anti-HIV activity

(2014) Baohua Zheng et al.   AIDS

Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice

(2014) Ariel Halper-Stromberg et al.   CELL

GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects

(2014) William Spreen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo

(2014) C Korin Bullen et al.   NATURE MEDICINE

Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor

(2014) Lu Lu et al.   Nature Communications

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

(2014) Thomas A Rasmussen et al.   Lancet HIV

HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain

(2012) Lu Lu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

(2012) N. M. Archin et al.   NATURE

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

(2012) Jinghe Huang et al.   NATURE

A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains

(2012) Lu Lu et al.   Retrovirology

Resistance of Human Immunodeficiency Virus Type 1 to a Third-Generation Fusion Inhibitor Requires Multiple Mutations in gp41 and Is Accompanied by a Dramatic Loss of gp41 Function

(2011) D. Eggink et al.   JOURNAL OF VIROLOGY

MR Molecular Imaging of Prostate Cancer with a Peptide-Targeted Contrast Agent in a Mouse Orthotopic Prostate Cancer Model

(2011) Mingqian Tan et al.   PHARMACEUTICAL RESEARCH

Cell-to-cell transmission of retroviruses: Innate immunity and interferon-induced restriction factors

(2011) Clare Jolly   VIROLOGY

Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults

(2008) J. M. Jacobson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Aspirin inhibits cytotoxicity of prion peptide PrP106-126 to neuronal cells associated with microglia activation in vitro

(2008) Lifeng Yang et al.   JOURNAL OF NEUROIMMUNOLOGY